Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 12-Month High - What's Next?

Key Points

• Alnylam Pharmaceuticals shares reached a new 52-week high of $455.34 during trading, marking a significant increase from the previous close of $448.91.
• Analysts have recently upgraded their price targets for Alnylam, with estimates ranging from $404.00 to $490.00, resulting in a consensus target price of $405.33 and a general rating of "Moderate Buy".
• Despite a reported revenue increase of 17.3% year-over-year, the company recorded a negative net margin of 12.96% for the last quarter.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) shares hit a new 52-week high during trading on Monday . The company traded as high as $455.00 and last traded at $455.34, with a volume of 189024 shares traded. The stock had previously closed at $448.91.

Analysts Set New Price Targets

Several brokerages have commented on ALNY. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective on the stock in a research note on Monday, August 4th. Piper Sandler lifted their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Chardan Capital upped their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Four equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market capitalization of $59.72 billion, a P/E ratio of -184.49 and a beta of 0.25. The business has a 50 day moving average of $345.09 and a 200-day moving average of $290.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter last year, the company earned ($0.13) EPS. The firm's revenue was up 17.3% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares of the company's stock, valued at $397,724.38. This represents a 97.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. This trade represents a 39.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,385 shares of company stock valued at $29,265,349. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $27,000. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $28,000. Whipplewood Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares during the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $30,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.